Key Highlights
- Moderna Inc.
- (NASDAQ:MRNA)’s shares are up by 16% over the past year and by 31% year-to-date.
- The stock has had a great start to 2026 as the firm made optimistic remarks related to its full-year 2025 revenue.
- During the JPMorgan Healthcare Conference, Moderna Inc.
- (NASDAQ:MRNA) raised the revenue guidance to $1.9 billion, which was close to the high end of the previous estimate of $1.6 billion to $2 billion.